The global transcriptomics market is following an intriguing and durable upwards path, with its the value forecast to go from USD 5,790.51Million in 2020 to USD 11,397.08 Million by 2030, at a compound annual growth rate (CAGR) of 7.0% for the period in question. The projection, showcased in a newly published 215-page Allied Market Research report spanning the forecast period of 2021–2030, manifests the growing connectivity of transcriptomics technologies across pharmaceutical and biotechnology research, clinical diagnostics, biomarker discovery and precision medicine development all around the world.
Operating within the specialized terrain of life sciences research that is the transcriptomics market, however, the underpinnings of market growth are rooted in structural, rather than discretionary scientific demand (the global mission to ascertain all levels of gene expression at the RNA level as a means of elucidating disease mechanisms, expediting drug discovery and developing diagnostic biomarkers as well as personalizing therapeutic interventions with a molecular fidelity unprecedented among earlier generations of tools).
Explore the Report Summary @
https://www.alliedmarketresearch.com/request-sample/2595
Transcriptomics 101: The Technology Behind Transcriptomic Analysis
Transcriptomics : the study of an organism’s transcriptome, i.e. the complete collection of RNA transcripts found in specific cell types, tissues and organisms at a specific point in time. In contrast to genomics, which studies the static DNA blueprint of an organism, transcriptomics analyzes the dynamic condition-dependent expression of genes — giving a real-time view of which genes are expressed to what degree in which subsets of cells and under what physiological or pathological contexts.
Its dynamism is the scientific power of transcriptomics. Transcriptomic comparisons can then be performed either across healthy and diseased tissues, or across drug-treated and untreated samples, or across developmental time points to help elucidate the molecular signatures that drive disease, identify novel therapeutic targets for drugs, classify mechanisms of action (MoAs), and derive expression-based diagnostic biomarkers with clinical relevance.
Transcriptomics is a data analysis field based on specific knowledge of RNA analysis technologies, which usually require that RNA molecules are reverse transcribed into complementary DNA (cDNA) for subsequent processing. Three core technology platforms serve as the basis for the field: microarrays — initially the high-throughput gene expression profiling platform, which is still heavily used in research laboratories; quantitative PCR (qPCR), which enables highly sensitive, quantitative measurement of targeted RNA through reverse transcription and polymerase chain reaction; and next-generation sequencing (NGS)–based RNA sequencing, which provides unbiased transcriptome-wide profiling with single-nucleotide resolution. One increasingly fruitful but still nascent frontier in this sequencing technology is single-cell RNA-sequencing (scRNA-seq), which resolves transcriptomic profiles at the level of individual cells — allowing for unprecedented insights into cellular heterogeneity, developmental trajectories, and disease microenvironments.
At the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), we have contributed to two landmark projects that generated transcriptome resources for researchers worldwide: the Mammalian Gene Collection Initiative and Mouse Transcriptome Project, both of which deliver essential reference resources that continue to fuel transcriptionomics-based discovery across the globe.
Prime Growth Drivers
Demand Catalyst – Personalized Medicine
The growing demand for personalized — or, precision — medicine presents the primary structure driver of transcriptomics market growth. The central tenet of precision medicine — to customize therapeutic interventions based on the specific molecular underpinnings of individual patients and their diseases — is inextricably linked to transcriptomic profiling as a means by which patient populations are stratified, optimal therapies selected, treatment responses predicted and disease progression monitored at the molecular level.
In oncology, in which the clinical impact of transcriptomics has been the most pronounced, RNA-sequencing-based tumor tissue gene expression profiling has become a routine element of treatment decision-making for several cancer types[4] (Table 1). Gene expression profiling informs chemotherapeutic regimen selection[5], immunotherapy candidate matching6 and targeted therapy identification[8]. With precision medicine moving beyond oncology into autoimmune disease, neurological disorders, cardiovascular diseases and rare diseases, the clinical application base for transcriptomics technologies is rapidly expanding and the demand for both research-use and IVD-grade transcriptomics products growing.
[1] Rising R&D spendings in Pharmaceutical and Biotechnology
Continued and increasing investment in pharmaceutical and biotechnology R&D provides a strong, direct driver for demand for transcriptomics consumables, instruments, software, and services. Transcriptomics is an important component of drug discovery and development pipelines, with applications at multiple stages of a program — target identification and validation, mechanism-of-action characterization, lead optimization, toxicogenomic safety assessment and companion diagnostic development. Therefore, all of the factors continued to contribute to underlying demand for transcriptomics tools and workflows, as global pharmaceutical R&D expenditure grows in tandem — fueled by an expanding pipeline of biologic and cell and gene therapy programs, accelerating adoption of AI-driven drug discovery, and vaccinated-focused expansion of vaccine/immunotherapy development post-pandemic.
The new era of RNA therapeutics — from mRNA vaccines and therapeutics, to small interfering RNA (siRNA) drugs, to antisense oligonucleotides — is driving a uniquely dynamic and fast-expanding demand segment for transcriptomics as the development and quality characterization of RNA-based drugs requires advanced transcriptomic analytical capabilities during different phases in their lifecycle.
Government Funding for Omics Research
A key organizer of growth in the transcriptomics market is government investment in genomics and omics research infrastructure, especially as it pertains to academics and translational research institutions which comprise a major end-user segment for transcriptomics products. Moreover, national and supranational funding programs — such as NIH grants in the USA or Horizon Europe funded research program — maintain a large base of transcriptomics product demand by supporting thousands of research laboratories around the world. The programs also support the development of transcriptome reference resources, analytical tools and clinical application research that enable additional downstream uses for transcriptomics and create new opportunities for commercial products.
Rise in RNA Sequencing Applications
The breakneck growth of instrumentation and applications for RNA sequencing — from bulk tissue RNA-seq to analyze differential gene expression, through single-cell RNA-seq for cellular heterogeneity profiling, through spatial transcriptomics for generation-level mapping of tissue-level expression, and long-read sequencing for full-length isoform characterization — is fueling a massive technology upgrade cycle in the transcriptomics market. Because the cost of sequencing reduces and its throughput increases, RNA-seq is increasingly replacing microarray-based methods in an ever wider variety of applications, while also enabling altogether new research and clinical questions that were previously impossible.
In particular, the continuous expansion in demand for more sensitive and complete transcriptomic capability within the research community continues to drive product innovation, illustrated by the launch of Trio RNA-Seq — a high-throughput end-to-end transcriptomics solution from NeuGen Technologies Inc., capable of detecting low-abundance transcripts. In June 2020, NanoString Technologies Inc. introduced new solutions specifically to study the immune response in COVID-19 disease research — highlighting the responsiveness of the market to advancing transcriptomics tools and technologies by meeting both scientific and public health needs in near real-time.
Discover more about this report @
https://www.alliedmarketresearch.com/purchase-enquiry/2595
Market Segmentation: Key Findings
By Type: Consumables Lead While Instruments and Software Grow
On the basis of type, it is bifurcated into four categories within the transcriptomics market: Consumables, Instruments, Software and Services. The consumables segment dominated the market in 2020, and the same segment is expected to retain its leadership status during the forecast period owing to dominant per-experiment recurring utilization model for laboratory reagent and kit procurement. Consumables — including RNA extraction kits, reverse transcription reagents, library preparation kits, sequencing reagents, microarray probe sets and qPCR master mixes — is the highest-volume; highest-frequency purchase category at every laboratory performing transcriptomics workflows. Consumables revenue scales with the overall installed base of transcriptomics instruments and number of experiments per laboratory.
Instruments segment is anticipated to experience significant growth over the analysis period considering factors including rising number of applications using genetic testing, increasing accessibility to benchtop sequencing instruments that are more cost effective for medium-size laboratories and growing investment by pharmaceuticals and biotechnology companies in setting up transcriptomics capabilities in-house. Software — including bioinformatics analysis pipelines, data management systems and visualisation tools — is a rapidly growing segment that points at the rising complexity and data richness of transcriptomics experiments, especially RNA-seq workflows capable of producing large datasets that pose analytical challenges.
By Region: NA, Europe HoldpoHaving Offset 10-Year Rebating MarketInflate.
The qPCR segment was found to be the greatest technology contributor in 2020, and it is anticipated to retain its leading position throughout the forecast timeline, on account of increased COVID-19-based genetic testing demand across healthcare systems globally, widespread adoption of qPCR for habitual gene expression quantification at research as well as clinical settings along with proven reliability and regulatory acceptance of this technology within diagnostic applications. The sensitivity, specificity, quantitative precision and relatively low per-sample cost of qPCR places it at the forefront as a workhorse technology for targeted transcriptomics applications spanning drug development, clinical diagnostics and quality control.
The next generation sequencing technology segment — which encompasses both next-generation short-read RNA-seq and emerging long-read sequencing platforms — is anticipated to grow most significantly over the forecast period, propelled by continuous advances in sequencing throughput and cost reduction, rapid adoption of single-cell RNA-seq in research and clinical discovery workflows, as well as clinical translation of spatial transcriptomics and liquid biopsy RNA seq applications are likely to drive revenue.
Microarrays still fulfil an extensive installed-base requirement within conventional research workflows, in agricultural genomics, toxicogenomics and clinical expression profiling applications in which the cost-effectiveness and simplicity of analysis offered by the technologies remains attractive.
By Application: Drug Discovery Leads; Diagnostics & Disease Profiling Increases
The largest contributor to the application segment in 2020 was drug discovery and it is anticipated that this will hold its dominance throughout the forecast period, validating transcriptomics’ crucial role in target identification, mechanism-of-action studies, biomarker discovery, toxicogenomics and companion diagnostic development across the pharmaceutical and biotechnology industries. Increasing new drug approvals — and the transcriptomics workflows necessary to support their development — establish a steady and growing demand base for this application segment.
Diagnostics and disease profiling segment to account for considerable revenue share during the forecast periodDue to progressive clinical translation of transcriptomic based diagnostic tests, expanding applications of gene expression profiling in treatment decision-making in oncology, and increased interest in RNA biomarkers for liquid biopsy applications for detection and monitoring of cancer, the diagnostics and disease profiling segment is anticipated to account for significant revenue share. The report’s CXO insights point to increased consumer awareness of preventive healthcare, rising demand for healthcare services from the general population and new advancement in technology, all of which are expected to widen transcriptomics scope area in clinical settings thereby driving segment growth.
Regional Analysis: North America Dominates, Asia-Pacific Fastest Growing
North America: Dominant Market Leader
The North American region accounted for the majority share of the global transcriptomics market in 2020 and is anticipated to maintain its dominance within the forecast period. This regional dominance is largely driven by a highly synergistic combination of the world’s biggest and most productive pharmaceutical and biotechnology sector — heavily concentrated in the U.S. especially — collectively an intense driver of transcriptomics research tools demand throughout the full drug development lifecycle; the highest concentration of leading academic and government research institutions, including this set of preeminent NIH-funded centers and major university research programs, representing an enduring broad base for demand for transcriptomics products;…and finally, the presence of many of the world’s foremost developers and commercial suppliers of transcriptomics technologies, directing their most advanced product innovations first toward home market fulfillment.
Impacts on Demand by RegionTechnological innovators continue to shape North American demand, with the U.S. leading as key market players establish new transcriptomics systems and drive research & development investments. Regulatory progress — notably, the Food and Drug Administration’s (FDA) growing embrace of RNA-based biomarker evidence in drug approvals submissions — adds to momentum for clinical translation of transcriptomics in the region.
Competitive Landscape
The global transcriptomics market is comprised of a mix of diversified life sciences instrument and reagent corporations, specialist genomics technology companies, and bioinformatics software providers. Companies mentioned in the report:
Agilent Technologies Inc.
Bio-Rad Laboratories Hoffmann-La Roche
Fluidigm Corporation
General Electric Company
Illumina Inc.
Merck & Co. Inc.
Promega Corporation
Qiagen Inc.
Thermo Fisher Scientific
Competition in this market hinges around multiple factors: the breadth and performance of instrument platforms spanning microarray, qPCR, and sequencing technology categories; the quality, sensitivity, and workflow compatibility/integratability of consumables and reagent kits; the capability and ease of use of bioinformatics software/data analysis pipelines; the depth of application-specific technical support/service infrastructure; as well as the speed and relevance with which new product solutions are developed to meet changing research/clinical workflow demands. The top players in the market have embraced product launch as their main growth strategy — appropriately so, given that ongoing innovation is paramount to capture and maintain competitive positioning amidst rapid technology capability evolution within this sector.
About Us:
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides end-to-end solutions along with information, education, advocacy, and networking resources to SMEs and early-stage start-ups to bring excellence to their processes. In addition, we offer a nurturing environment required to develop and grow businesses, including business planning; virtual support; market intelligence; acquiring resources; and getting direct access to finance, suppliers, and other experts to boost the growth of businesses and entrepreneurs.
Our bundled and hassle-free business support systems are customized to meet the needs of SME consultants and industry leaders. Moreover, our large network of skilled consultants and experts help start-ups get the business on a roll.
Contact:
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
[email protected]
